{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:38:27Z","timestamp":1791517107004,"version":"4.3.4"},"reference-count":194,"publisher":"Harborside Press, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"\n Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications have been identified. Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed\/refractory CLL\/SLL. The selection of treatment is based on the disease stage, presence or absence of del(17p) or\n TP53<\/jats:italic>\n mutation, immunoglobulin heavy chain variable region mutation status, patient age, performance status, comorbid conditions, and the agent\u2019s toxicity profile. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL\/SLL.\n <\/jats:p>","DOI":"10.6004\/jnccn.2024.0018","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T16:12:24Z","timestamp":1713283944000},"page":"175-204","source":"Crossref","is-referenced-by-count":70,"title":["Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, Version 2.2024"],"prefix":"10.6004","volume":"22","author":[{"given":"William G.","family":"Wierda","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Brown","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh","family":"Awan","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed F.","family":"Bilgrami","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Bociek","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Brander","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cortese","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Cripe","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall S.","family":"Davis","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Eradat","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Fakhri","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Fletcher","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameh","family":"Gaballa","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Saad","family":"Hamid","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hill","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kaesberg","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Ma","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Mosse","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Nakhoda","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Parikh","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Schorr","sequence":"additional","affiliation":[{"name":"Patient advocate"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Schuster","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav","family":"Seshadri","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Stephens","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Thompson","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitra","family":"Ujjani","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Valdez","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Wagner-Johnston","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Sundar","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Dwyer","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"J Clin Oncol","first-page":"4648","article-title":"Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center","volume":"25","author":"Tsimberidou AM","year":"2007","unstructured":"Tsimberidou AM, Wen S, O\u2019Brien S, Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2007;25:4648\u20134656."},{"key":"B2","series-title":"CA Cancer J Clin","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12\u201349."},{"key":"B3","series-title":"Blood","first-page":"219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai KR","year":"1975","unstructured":"Rai KR, Sawitsky A, Cronkite EP, Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219\u2013234."},{"key":"B4","series-title":"Cancer","first-page":"198","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet JL","year":"1981","unstructured":"Binet JL, Auquier A, Dighiero G, A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198\u2013206."},{"key":"B5","series-title":"J Clin Oncol","first-page":"3059","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson BD","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059\u20133068."},{"key":"B6","series-title":"Haematologica","first-page":"465","article-title":"Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome","volume":"90","author":"Tobin G","year":"2005","unstructured":"Tobin G, Thunberg U, Laurell A, Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome. Haematologica 2005;90:465\u2013469."},{"key":"B7","series-title":"Br J Haematol","first-page":"127","article-title":"The outcome of chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity","volume":"173","author":"Davis Z","year":"2016","unstructured":"Davis Z, Forconi F, Parker A, The outcome of chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity. Br J Haematol 2016;173:127\u2013136."},{"key":"B8","series-title":"Am J Hematol","first-page":"E216","article-title":"Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: mutational load or mutational status? Analysis of 1003 cases","volume":"93","author":"Morabito F","year":"2018","unstructured":"Morabito F, Shanafelt TD, Gentile M, Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: mutational load or mutational status? Analysis of 1003 cases. Am J Hematol 2018;93:E216\u2013219."},{"key":"B9","series-title":"Br J Haematol","first-page":"33","article-title":"The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab","volume":"180","author":"Jain P","year":"2018","unstructured":"Jain P, Nogueras Gonz\u00e1lez GM, Kanagal-Shamanna R, The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol 2018;180:33\u201340."},{"key":"B10","series-title":"Blood","first-page":"208","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer K","year":"2016","unstructured":"Fischer K, Bahlo J, Fink AM, Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 2016;127:208\u2013215."},{"key":"B11","series-title":"Lancet Oncol","first-page":"928","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst B","year":"2016","unstructured":"Eichhorst B, Fink AM, Bahlo J, First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016;17:928\u2013942."},{"key":"B12","series-title":"Blood","first-page":"1784","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson PA","year":"2023","unstructured":"Thompson PA, Bazinet A, Wierda WG, Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up. Blood 2023;142:1784\u20131788."},{"key":"B13","series-title":"Blood","first-page":"1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle RN","year":"1999","unstructured":"Damle RN, Wasil T, Fais F, Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840\u20131847."},{"key":"B14","series-title":"Blood","first-page":"1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin TJ","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848\u20131854."},{"key":"B15","series-title":"Blood","first-page":"2262","article-title":"Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia","volume":"99","author":"Tobin G","year":"2002","unstructured":"Tobin G, Thunberg U, Johnson A, Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99:2262\u20132264."},{"key":"B16","series-title":"Blood","first-page":"1177","article-title":"Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors","volume":"100","author":"Oscier DG","year":"2002","unstructured":"Oscier DG, Gardiner AC, Mould SJ, Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177\u20131184."},{"key":"B17","series-title":"Haematologica","first-page":"1705","article-title":"Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation","volume":"95","author":"Oscier D","year":"2010","unstructured":"Oscier D, Wade R, Davis Z, Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 2010;95:1705\u20131712."},{"key":"B18","series-title":"Blood Adv","first-page":"3440","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr PM","year":"2022","unstructured":"Barr PM, Owen C, Robak T, Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv 2022;6:3440\u20133450."},{"key":"B19","series-title":"Leukemia","first-page":"1171","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman JP","year":"2022","unstructured":"Sharman JP, Egyed M, Jurczak W, Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia. Leukemia 2022;36:1171\u20131175."},{"key":"B20","series-title":"Lancet Oncol","first-page":"1031","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam CS","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol 2022;23:1031\u20131043."},{"key":"B21","series-title":"Blood","first-page":"112","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt TD","year":"2022","unstructured":"Shanafelt TD, Wang XV, Hanson CA, Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood 2022;140:112\u2013120."},{"key":"B22","series-title":"Blood","first-page":"1902","article-title":"Broad superiority of zanubrutinib (Zanu) over bendamustine + rituximab (BR) across multiple high-risk factors: biomarker subgroup analysis in the phase 3 SEQUOIA study in Patients with treatment-naive (TN) Chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) without del(17p)","volume":"142","author":"Ramakrishnan V","year":"2023","unstructured":"Ramakrishnan V, Xu L, Paik JC, Broad superiority of zanubrutinib (Zanu) over bendamustine + rituximab (BR) across multiple high-risk factors: biomarker subgroup analysis in the phase 3 SEQUOIA study in Patients with treatment-naive (TN) Chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) without del(17p). Blood 2023;142(Suppl 1):1902."},{"key":"B23","series-title":"Lancet Oncol","first-page":"535","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen P","year":"2023","unstructured":"Hillmen P, Pitchford A, Bloor A, Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2023;24:535\u2013552."},{"key":"B24","series-title":"J Clin Oncol","first-page":"4049","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf O","year":"2021","unstructured":"Al-Sawaf O, Zhang C, Lu T, Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol 2021;39:4049\u20134060."},{"key":"B25","series-title":"Nat Commun","first-page":"2147","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf O","year":"2023","unstructured":"Al-Sawaf O, Zhang C, Jin HY, Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun 2023;14:2147."},{"key":"B26","series-title":"N Engl J Med","first-page":"1739","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst B","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med 2023;388:1739\u20131754."},{"key":"B27","series-title":"Blood","first-page":"Abstract 635","article-title":"First-line venetoclax combinations in fit patients with CLL: 4-year follow-up and NGS-based MRD analysis from the phase 3 GAIA\/CLL13 trial","volume":"142","author":"F\u00fcrstenau M","year":"2023","unstructured":"F\u00fcrstenau M, Ritgen M, Robrecht S, First-line venetoclax combinations in fit patients with CLL: 4-year follow-up and NGS-based MRD analysis from the phase 3 GAIA\/CLL13 trial. Blood 2023;142(Suppl 1):Abstract 635."},{"key":"B28","series-title":"N Engl J Med","first-page":"1910","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner H","year":"2000","unstructured":"D\u00f6hner H, Stilgenbauer S, Benner A, Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910\u20131916."},{"key":"B29","series-title":"Blood","first-page":"957","article-title":"De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience","volume":"114","author":"Tam CS","year":"2009","unstructured":"Tam CS, Shanafelt TD, Wierda WG, De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 2009;114:957\u2013964."},{"key":"B30","series-title":"Br J Haematol","first-page":"105","article-title":"The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience","volume":"173","author":"Van Dyke DL","year":"2016","unstructured":"Van Dyke DL, Werner L, Rassenti LZ, The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. Br J Haematol 2016;173:105\u2013113."},{"key":"B31","series-title":"Haematologica","first-page":"1242","article-title":"Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival","volume":"92","author":"Stilgenbauer S","year":"2007","unstructured":"Stilgenbauer S, Sander S, Bullinger L, Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007;92:1242\u20131245."},{"key":"B32","series-title":"Clin Cancer Res","first-page":"995","article-title":"The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness","volume":"15","author":"Rossi D","year":"2009","unstructured":"Rossi D, Cerri M, Deambrogi C, The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15:995\u20131004."},{"key":"B33","series-title":"J Clin Oncol","first-page":"4473","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz T","year":"2010","unstructured":"Zenz T, Eichhorst B, Busch R, TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:4473\u20134479."},{"key":"B34","series-title":"Blood","first-page":"3247","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer S","year":"2014","unstructured":"Stilgenbauer S, Schnaiter A, Paschka P, Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123:3247\u20133254."},{"key":"B35","series-title":"N Engl J Med","first-page":"2517","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach JA","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379:2517\u20132528."},{"key":"B36","series-title":"Blood","first-page":"Abstract 639","article-title":"Long-term results of Alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy","volume":"138","author":"Woyach JA","year":"2021","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Long-term results of Alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy. Blood 2021;138(Suppl 1):Abstract 639."},{"key":"B37","series-title":"Blood","first-page":"2402","article-title":"Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax","volume":"135","author":"Tausch E","year":"2020","unstructured":"Tausch E, Schneider C, Robrecht S, Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood 2020;135:2402\u20132412."},{"key":"B38","series-title":"Blood","first-page":"3284","article-title":"TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial","volume":"121","author":"Dreger P","year":"2013","unstructured":"Dreger P, Schnaiter A, Zenz T, TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood 2013;121:3284\u20133288."},{"key":"B39","series-title":"Blood","first-page":"1266","article-title":"NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG","volume":"122","author":"Schnaiter A","year":"2013","unstructured":"Schnaiter A, Paschka P, Rossi M, NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood 2013;122:1266\u20131270."},{"key":"B40","series-title":"Blood","first-page":"2378","article-title":"Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness","volume":"123","author":"Messina M","year":"2014","unstructured":"Messina M, Del Giudice I, Khiabanian H, Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood 2014;123:2378\u20132388."},{"key":"B41","series-title":"Blood","first-page":"2122","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu F","year":"2016","unstructured":"Nadeu F, Delgado J, Royo C, Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood 2016;127:2122\u20132130."},{"key":"B42","series-title":"Leukemia","first-page":"1760","article-title":"Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial","volume":"34","author":"Blakemore SJ","year":"2020","unstructured":"Blakemore SJ, Clifford R, Parker H, Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial. Leukemia 2020;34:1760\u20131774."},{"key":"B43","series-title":"Blood","first-page":"1403","article-title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia","volume":"121","author":"Rossi D","year":"2013","unstructured":"Rossi D, Rasi S, Spina V, Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013;121:1403\u20131412."},{"key":"B44","series-title":"Blood","first-page":"1205","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact","volume":"133","author":"Baliakas P","year":"2019","unstructured":"Baliakas P, Jeromin S, Iskas M, Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood 2019;133:1205\u20131216."},{"key":"B45","series-title":"Cancer","first-page":"3612","article-title":"Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens","volume":"121","author":"Thompson PA","year":"2015","unstructured":"Thompson PA, O\u2019Brien SM, Wierda WG, Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 2015;121:3612\u20133621."},{"key":"B46","series-title":"Hematol Oncol","first-page":"664","article-title":"Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia","volume":"35","author":"Le Bris Y","year":"2017","unstructured":"Le Bris Y, Struski S, Gui\u00e8ze R, Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia. Hematol Oncol 2017;35:664\u2013670."},{"key":"B47","series-title":"Oncotarget","first-page":"54297","article-title":"Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53\/ATM FISH deletions","volume":"8","author":"Puiggros A","year":"2017","unstructured":"Puiggros A, Collado R, Calasanz MJ, Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53\/ATM FISH deletions. Oncotarget 2017;8:54297\u201354303."},{"key":"B48","series-title":"J Clin Oncol","first-page":"1437","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach JA","year":"2017","unstructured":"Woyach JA, Ruppert AS, Guinn D, BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol 2017;35:1437\u20131443."},{"key":"B49","series-title":"Blood","first-page":"446","article-title":"High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations","volume":"142","author":"F\u00fcrstenau M","year":"2023","unstructured":"F\u00fcrstenau M, Thus YJ, Robrecht S, High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations. Blood 2023;142:446\u2013459."},{"key":"B50","series-title":"J Clin Oncol","first-page":"1637","article-title":"Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment","volume":"27","author":"Wierda WG","year":"2009","unstructured":"Wierda WG, O\u2019Brien S, Wang X, Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 2009;27:1637\u20131643."},{"key":"B51","series-title":"Cancer","first-page":"565","article-title":"\u03b22 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia","volume":"122","author":"Thompson PA","year":"2016","unstructured":"Thompson PA, O\u2019Brien SM, Xiao L, \u03b22 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer 2016;122:565\u2013573."},{"key":"B52","series-title":"Lancet Oncol","first-page":"779","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","unstructured":"International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 2016;17:779\u2013790."},{"key":"B53","series-title":"Blood","first-page":"4679","article-title":"Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia","volume":"109","author":"Wierda WG","year":"2007","unstructured":"Wierda WG, O\u2019Brien S, Wang X, Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007;109:4679\u20134685."},{"key":"B54","series-title":"J Clin Oncol","first-page":"576","article-title":"Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model","volume":"39","author":"Ahn IE","year":"2021","unstructured":"Ahn IE, Tian X, Ipe D, Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model. J Clin Oncol 2021;39:576\u2013585."},{"key":"B55","series-title":"Lancet Haematol","first-page":"e366","article-title":"Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations","volume":"6","author":"Soumerai JD","year":"2019","unstructured":"Soumerai JD, Ni A, Darif M, Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol 2019;6:e366\u2013374."},{"key":"B56","series-title":"Cancer","first-page":"363","article-title":"Validation of a new prognostic index for patients with chronic lymphocytic leukemia","volume":"115","author":"Shanafelt TD","year":"2009","unstructured":"Shanafelt TD, Jenkins G, Call TG, Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 2009;115:363\u2013372."},{"key":"B57","series-title":"Haematologica","first-page":"464","article-title":"The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience","volume":"95","author":"Molica S","year":"2010","unstructured":"Molica S, Mauro FR, Callea V, The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. Haematologica 2010;95:464\u2013469."},{"key":"B58","series-title":"J Clin Oncol","first-page":"4088","article-title":"Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia","volume":"29","author":"Wierda WG","year":"2011","unstructured":"Wierda WG, O\u2019Brien S, Wang X, Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 2011;29:4088\u20134095."},{"key":"B59","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"612","article-title":"Integrated CLL scoring system, a new and simple index to predict time to treatment and overall survival in patients with chronic lymphocytic leukemia","volume":"15","author":"Visentin A","year":"2015","unstructured":"Visentin A, Facco M, Frezzato F, Integrated CLL scoring system, a new and simple index to predict time to treatment and overall survival in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 2015;15:612\u2013620.e5."},{"key":"B60","series-title":"Eur J Haematol","first-page":"703","article-title":"Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment","volume":"101","author":"Gentile M","year":"2018","unstructured":"Gentile M, Shanafelt TD, Mauro FR, Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. Eur J Haematol 2018;101:703\u2013706."},{"key":"B61","series-title":"Blood","first-page":"1859","article-title":"International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia","volume":"135","author":"Condoluci A","year":"2020","unstructured":"Condoluci A, Terzi di Bergamo L, Langerbeins P, International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood 2020;135:1859\u20131869."},{"key":"B62","series-title":"Blood","first-page":"2745","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek M","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018;131:2745\u20132760."},{"key":"B63","series-title":"Blood","first-page":"1810","article-title":"Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy","volume":"123","author":"Woyach JA","year":"2014","unstructured":"Woyach JA, Smucker K, Smith LL, Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 2014;123:1810\u20131817."},{"key":"B64","series-title":"J Clin Oncol","first-page":"2820","article-title":"Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia","volume":"30","author":"Cheson BD","year":"2012","unstructured":"Cheson BD, Byrd JC, Rai KR, Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012;30:2820\u20132822."},{"key":"B65","series-title":"Cytometry B Clin Cytom","first-page":"121","article-title":"Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project","volume":"94","author":"Rawstron AC","year":"2018","unstructured":"Rawstron AC, Kreuzer KA, Soosapilla A, Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom 2018;94:121\u2013128."},{"key":"B66","series-title":"Leukemia","first-page":"3059","article-title":"Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations","volume":"35","author":"Wierda WG","year":"2021","unstructured":"Wierda WG, Rawstron A, Cymbalista F, Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia 2021;35:3059\u20133072."},{"key":"B67","series-title":"Proc Natl Acad Sci USA","first-page":"21194","article-title":"High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment","volume":"108","author":"Logan AC","year":"2011","unstructured":"Logan AC, Gao H, Wang C, High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proc Natl Acad Sci USA 2011;108:21194\u201321199."},{"key":"B68","series-title":"Leukemia","first-page":"929","article-title":"A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study","volume":"30","author":"Rawstron AC","year":"2016","unstructured":"Rawstron AC, Fazi C, Agathangelidis A, A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia 2016;30:929\u2013936."},{"key":"B69","series-title":"Leuk Lymphoma","first-page":"1986","article-title":"Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry","volume":"59","author":"Aw A","year":"2018","unstructured":"Aw A, Kim HT, Fernandes SM, Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry. Leuk Lymphoma 2018;59:1986\u20131989."},{"key":"B70","series-title":"Blood","first-page":"1951","article-title":"Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy","volume":"134","author":"Thompson PA","year":"2019","unstructured":"Thompson PA, Srivastava J, Peterson C, Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood 2019;134:1951\u20131959."},{"key":"B71","series-title":"Leukemia","first-page":"142","article-title":"Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL","volume":"27","author":"Rawstron AC","year":"2013","unstructured":"Rawstron AC, B\u00f6ttcher S, Letestu R, Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 2013;27:142\u2013149."},{"key":"B72","series-title":"Br J Haematol","first-page":"360","article-title":"Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR","volume":"166","author":"Raponi S","year":"2014","unstructured":"Raponi S, Della Starza I, De Propris MS, Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. Br J Haematol 2014;166:360\u2013368."},{"key":"B73","series-title":"Haematologica","first-page":"2108","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno C","year":"2022","unstructured":"Moreno C, Greil R, Demirkan F, First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica 2022;107:2108\u20132120."},{"key":"B74","series-title":"Blood","first-page":"2810","article-title":"Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib","volume":"138","author":"Wang XV","year":"2021","unstructured":"Wang XV, Hanson CA, Tschumper RC, Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood 2021;138:2810\u20132827."},{"key":"B75","series-title":"J Clin Oncol","first-page":"3758","article-title":"Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group","volume":"34","author":"Kovacs G","year":"2016","unstructured":"Kovacs G, Robrecht S, Fink AM, Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol 2016;34:3758\u20133765."},{"key":"B76","series-title":"Leukemia","first-page":"2388","article-title":"Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies","volume":"32","author":"Thompson PA","year":"2018","unstructured":"Thompson PA, Peterson CB, Strati P, Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 2018;32:2388\u20132398."},{"key":"B77","series-title":"Blood","first-page":"3278","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam CS","year":"2022","unstructured":"Tam CS, Allan JN, Siddiqi T, Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood 2022;139:3278\u20133289."},{"key":"B78","series-title":"J Clin Oncol","first-page":"3853","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE Study","volume":"39","author":"Wierda WG","year":"2021","unstructured":"Wierda WG, Allan JN, Siddiqi T, Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE Study. J Clin Oncol 2021;39:3853\u20133865."},{"key":"B79","series-title":"Blood","first-page":"224","article-title":"Treatment outcomes after undetectable MRD with first-line ibrutinib (Ibr) plus venetoclax (Ven): fixed duration treatment (placebo) versus continued Ibr with up to 5 years median follow-up in the CAPTIVATE Study","volume":"140","author":"Allan JN","year":"2022","unstructured":"Allan JN, Siddiqi T, Kipps TJ, Treatment outcomes after undetectable MRD with first-line ibrutinib (Ibr) plus venetoclax (Ven): fixed duration treatment (placebo) versus continued Ibr with up to 5 years median follow-up in the CAPTIVATE Study. Blood 2022;140(Suppl 1):224\u2013227."},{"key":"B80","series-title":"NEJM Evid","first-page":"EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater AP","year":"2022","unstructured":"Kater AP, Owen C, Moreno C, Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid 2022;1:EVIDoa2200006."},{"key":"B81","series-title":"J Clin Oncol","first-page":"3689","article-title":"Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib- venetoclax versus chlorambucil-obinutuzumab in the GLOW study","volume":"41","author":"Munir T","year":"2023","unstructured":"Munir T, Moreno C, Owen C, Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib- venetoclax versus chlorambucil-obinutuzumab in the GLOW study. J Clin Oncol 2023;41:3689\u20133699."},{"key":"B82","series-title":"Blood","first-page":"Abstract 634","article-title":"First-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): 55-month follow-up from the Glow Study","volume":"142","author":"Moreno C","year":"2023","unstructured":"Moreno C, Munir T, Owen C, First-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): 55-month follow-up from the Glow Study. Blood 2023; 142(Suppl 1):Abstract 634."},{"key":"B83","series-title":"Blood","first-page":"231","article-title":"Combination of Ibrutinib plus venetoclax with MRD-driven Duration of treatment results in a higher rate of MRD negativity in IGHV unmutated than mutated CLL: updated interim analysis of FLAIR Study","volume":"140","author":"Munir T","year":"2022","unstructured":"Munir T, Pitchford A, Bloor A, Combination of Ibrutinib plus venetoclax with MRD-driven Duration of treatment results in a higher rate of MRD negativity in IGHV unmutated than mutated CLL: updated interim analysis of FLAIR Study. Blood 2022;140(Suppl 1):231\u2013233."},{"key":"B84","series-title":"Blood","first-page":"Abstract 631","article-title":"Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: report of the phase III UK NCRI FLAIR Study","volume":"142","author":"Hillmen P","year":"2023","unstructured":"Hillmen P, Cairns DA, Bloor AJC, Ibrutinib plus venetoclax with MRD-directed duration of treatment is superior to FCR and is a new standard of care for previously untreated CLL: report of the phase III UK NCRI FLAIR Study. Blood 2023;142(Suppl 1):Abstract 631."},{"key":"B85","series-title":"J Clin Oncol","first-page":"269","article-title":"Fixed duration of venetoclax- rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","author":"Kater AP","year":"2019","unstructured":"Kater AP, Seymour JF, Hillmen P, Fixed duration of venetoclax- rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol 2019;37:269\u2013277."},{"key":"B86","series-title":"Blood","first-page":"839","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour JF","year":"2022","unstructured":"Seymour JF, Kipps TJ, Eichhorst BF, Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab. Blood 2022;140:839\u2013850."},{"key":"B87","series-title":"J Clin Oncol","first-page":"4042","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater AP","year":"2020","unstructured":"Kater AP, Wu JQ, Kipps T, Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol 2020;38:4042\u20134054."},{"key":"B88","series-title":"J Clin Oncol","first-page":"2722","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY Study","volume":"37","author":"Hillmen P","year":"2019","unstructured":"Hillmen P, Rawstron AC, Brock K, Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY Study. J Clin Oncol 2019;37:2722\u20132729."},{"key":"B89","series-title":"Blood","first-page":"222","article-title":"MRD4 eradication at 6 months and early clearance of MRD with combination of ibrutinib plus venetoclax results in sustained clinical and MRD responses: exploratory analysis of the blood cancer UK TAP Clarity Study","volume":"140","author":"Munir T","year":"2022","unstructured":"Munir T, Cherrill LR, Webster N, MRD4 eradication at 6 months and early clearance of MRD with combination of ibrutinib plus venetoclax results in sustained clinical and MRD responses: exploratory analysis of the blood cancer UK TAP Clarity Study. Blood 2022;140(Suppl 1):222\u2013223."},{"key":"B90","series-title":"Blood","first-page":"2975","article-title":"LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis","volume":"116","author":"Gutierrez A Jr","year":"2010","unstructured":"Gutierrez A Jr, Tschumper RC, Wu X, LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood 2010;116:2975\u20132983."},{"key":"B91","series-title":"Leuk Res","first-page":"1212","article-title":"CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia","volume":"33","author":"Palumbo GA","year":"2009","unstructured":"Palumbo GA, Parrinello N, Fargione G, CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res 2009;33:1212\u20131216."},{"key":"B92","series-title":"Cytometry B Clin Cytom","first-page":"98","article-title":"CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry","volume":"86","author":"Sandes AF","year":"2014","unstructured":"Sandes AF, de Lourdes Chauffaille M, Oliveira CR, CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry. Cytometry B Clin Cytom 2014;86:98\u2013105."},{"key":"B93","series-title":"J Clin Pathol","first-page":"473","article-title":"LEF1: a highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia\/small lymphocytic B cell lymphoma","volume":"68","author":"Menter T","year":"2015","unstructured":"Menter T, Dirnhofer S, Tzankov A. LEF1: a highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia\/small lymphocytic B cell lymphoma. J Clin Pathol 2015;68:473\u2013478."},{"key":"B94","series-title":"Blood","first-page":"3152","article-title":"Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression","volume":"108","author":"Dicker F","year":"2006","unstructured":"Dicker F, Schnittger S, Haferlach T, Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006;108:3152\u20133160."},{"key":"B95","series-title":"Cancer Genet Cytogenet","first-page":"134","article-title":"Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) study","volume":"203","author":"Heerema NA","year":"2010","unstructured":"Heerema NA, Byrd JC, Dal Cin PS, Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) study. Cancer Genet Cytogenet 2010;203:134\u2013140."},{"key":"B96","series-title":"N Engl J Med","first-page":"575","article-title":"Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia","volume":"359","author":"Rawstron AC","year":"2008","unstructured":"Rawstron AC, Bennett FL, O\u2019Connor SJ, Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008;359:575\u2013583."},{"key":"B97","series-title":"Br J Haematol","first-page":"64","article-title":"The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors","volume":"146","author":"Rossi D","year":"2009","unstructured":"Rossi D, Sozzi E, Puma A, The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol 2009;146:64\u201375."},{"key":"B98","series-title":"Br J Haematol","first-page":"325","article-title":"Diagnostic criteria for monoclonal B-cell lymphocytosis","volume":"130","author":"Marti GE","year":"2005","unstructured":"Marti GE, Rawstron AC, Ghia P, Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 2005;130:325\u2013332."},{"key":"B99","series-title":"Cytometry B Clin Cytom","first-page":"S19","article-title":"Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL)","volume":"78","author":"Rawstron AC","year":"2010","unstructured":"Rawstron AC, Shanafelt T, Lanasa MC, Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). Cytometry B Clin Cytom 2010;78(Suppl 1):S19\u201323."},{"key":"B100","series-title":"Blood","first-page":"2375","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow SH","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375\u20132390."},{"key":"B101","series-title":"J Clin Oncol","first-page":"3959","article-title":"Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia","volume":"27","author":"Shanafelt TD","year":"2009","unstructured":"Shanafelt TD, Kay NE, Rabe KG, Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol 2009;27:3959\u20133963."},{"key":"B102","series-title":"Haematologica","first-page":"1144","article-title":"Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis","volume":"96","author":"Gibson SE","year":"2011","unstructured":"Gibson SE, Swerdlow SH, Ferry JA, Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis. Haematologica 2011;96:1144\u20131152."},{"key":"B103","series-title":"Leuk Lymphoma","first-page":"2079","article-title":"Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"55","author":"Conte MJ","year":"2014","unstructured":"Conte MJ, Bowen DA, Wiseman GA, Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma. Leuk Lymphoma 2014;55:2079\u20132084."},{"key":"B104","series-title":"Blood","first-page":"2783","article-title":"Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia","volume":"123","author":"Falchi L","year":"2014","unstructured":"Falchi L, Keating MJ, Marom EM, Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood 2014;123:2783\u20132790."},{"key":"B105","series-title":"J Clin Oncol","first-page":"440","article-title":"Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies","volume":"31","author":"Woyach JA","year":"2013","unstructured":"Woyach JA, Ruppert AS, Rai K, Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol 2013;31:440\u2013447."},{"key":"B106","series-title":"Haematologica","first-page":"1095","article-title":"Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials","volume":"99","author":"Goede V","year":"2014","unstructured":"Goede V, Cramer P, Busch R, Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica 2014;99:1095\u20131100."},{"key":"B107","series-title":"J Am Geriatr Soc","first-page":"1926","article-title":"A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients","volume":"56","author":"Salvi F","year":"2008","unstructured":"Salvi F, Miller MD, Grilli A, A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 2008;56:1926\u20131931."},{"key":"B108","series-title":"N Engl J Med","first-page":"2225","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer K","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019;380:2225\u20132236."},{"key":"B109","series-title":"Lancet Oncol","first-page":"1188","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf O","year":"2020","unstructured":"Al-Sawaf O, Zhang C, Tandon M, Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2020;21:1188\u20131200."},{"key":"B110","series-title":"Leukemia","first-page":"2038","article-title":"Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial","volume":"34","author":"Herling CD","year":"2020","unstructured":"Herling CD, Cymbalista F, Gro\u00df-Ophoff-M\u00fcller C, Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia 2020;34:2038\u20132050."},{"key":"B111","series-title":"Blood","first-page":"Abstract 199","article-title":"Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial","volume":"142","author":"Riecke A","year":"2023","unstructured":"Riecke A, Tausch E, Yosifov DY, Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial. Blood 2023;142(Suppl 1):Abstract 199."},{"key":"B112","series-title":"Blood","first-page":"Abstract 636","article-title":"Acalabrutinib \u00b1 obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of elevate-TN","volume":"142","author":"Sharman JP","year":"2023","unstructured":"Sharman JP, Egyed M, Jurczak W, Acalabrutinib \u00b1 obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of elevate-TN. Blood 2023;142(Suppl 1):Abstract 636."},{"key":"B113","series-title":"J Clin Oncol","first-page":"3441","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd JC","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 2021;39:3441\u20133452."},{"key":"B114","series-title":"Leukemia","first-page":"787","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger JA","year":"2020","unstructured":"Burger JA, Barr PM, Robak T, Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 2020;34:787\u2013798."},{"key":"B115","series-title":"N Engl J Med","first-page":"432","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt TD","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 2019;381:432\u2013443."},{"key":"B116","series-title":"N Engl J Med","first-page":"319","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown JR","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2023;388:319\u2013332."},{"key":"B117","series-title":"Blood","first-page":"1011","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger JA","year":"2019","unstructured":"Burger JA, Sivina M, Jain N, Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 2019;133:1011\u20131019."},{"key":"B118","series-title":"HemaSphere","first-page":"e336","article-title":"Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 trial of the GCLLSG)","volume":"4","author":"Kutsch N","year":"2020","unstructured":"Kutsch N, Bahlo J, Robrecht S, Long term follow-up data and health-related quality of life in frontline therapy of fit patients treated with FCR versus BR (CLL10 trial of the GCLLSG). HemaSphere 2020;4:e336."},{"key":"B119","series-title":"Haematologica","first-page":"698","article-title":"Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study","volume":"103","author":"Michallet AS","year":"2018","unstructured":"Michallet AS, Aktan M, Hiddemann W, Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Haematologica 2018;103:698\u2013706."},{"key":"B120","series-title":"Leuk Lymphoma","first-page":"791","article-title":"Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia","volume":"62","author":"Sharman JP","year":"2021","unstructured":"Sharman JP, Burke JM, Yimer HA, Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia. Leuk Lymphoma 2021;62:791\u2013800."},{"key":"B121","series-title":"Blood","first-page":"79","article-title":"Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia","volume":"127","author":"Byrd JC","year":"2016","unstructured":"Byrd JC, Flynn JM, Kipps TJ, Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood 2016;127:79\u201386."},{"key":"B122","series-title":"Br J Haematol","first-page":"325","article-title":"Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed\/refractory chronic lymphocytic leukaemia patients: final analysis of the Phase IIIb GREEN study","volume":"193","author":"Stilgenbauer S","year":"2021","unstructured":"Stilgenbauer S, Bosch F, Ilhan O, Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed\/refractory chronic lymphocytic leukaemia patients: final analysis of the Phase IIIb GREEN study. Br J Haematol 2021;193:325\u2013338."},{"key":"B123","series-title":"Leukemia","first-page":"1602","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study","volume":"29","author":"Goede V","year":"2015","unstructured":"Goede V, Fischer K, Engelke A, Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia 2015;29:1602\u20131604."},{"key":"B124","series-title":"Leukemia","first-page":"1779","article-title":"Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia","volume":"23","author":"Castro JE","year":"2009","unstructured":"Castro JE, James DF, Sandoval-Sus JD, Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009;23:1779\u20131789."},{"key":"B125","series-title":"Blood","first-page":"Abstract 1730","article-title":"Obinutuzumab (Gazyva) and high-dose methylprednisolone (HDMP) combination for patients with chronic lymphocytic leukemia (CLL) - a phase Ib\/II study","volume":"130","author":"Castro JE","year":"2017","unstructured":"Castro JE, Amaya-Chanaga CI, Velez Lujan J, Obinutuzumab (Gazyva) and high-dose methylprednisolone (HDMP) combination for patients with chronic lymphocytic leukemia (CLL) - a phase Ib\/II study. Blood 2017;130(Suppl 1):Abstract 1730."},{"key":"B126","series-title":"N Engl J Med","first-page":"498","article-title":"Ibrutinib for chronic lymphocytic leukemia with TP53 alterations","volume":"383","author":"Ahn IE","year":"2020","unstructured":"Ahn IE, Tian X, Wiestner A. Ibrutinib for chronic lymphocytic leukemia with TP53 alterations. N Engl J Med 2020;383:498\u2013500."},{"key":"B127","series-title":"Br J Haematol","first-page":"947","article-title":"Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a\u2009pooled analysis from four clinical trials","volume":"196","author":"Allan JN","year":"2022","unstructured":"Allan JN, Shanafelt T, Wiestner A, Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a\u2009pooled analysis from four clinical trials. Br J Haematol 2022;196:947\u2013953."},{"key":"B128","series-title":"Haematologica","first-page":"2354","article-title":"Zanubrutinib monotherapy for patients with treatment na\u00efve chronic lymphocytic leukemia and 17p deletion","volume":"106","author":"Tam CS","year":"2020","unstructured":"Tam CS, Robak T, Ghia P, Zanubrutinib monotherapy for patients with treatment na\u00efve chronic lymphocytic leukemia and 17p deletion. Haematologica 2020;106:2354\u20132363."},{"key":"B129","series-title":"HemaSphere","first-page":"e801","article-title":"Acalabrutinib versus investigator\u2019s choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND Trial results","volume":"6","author":"Ghia P","year":"2022","unstructured":"Ghia P, Pluta A, Wach M, Acalabrutinib versus investigator\u2019s choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND Trial results. HemaSphere 2022;6:e801."},{"key":"B130","series-title":"Am J Hematol","first-page":"1353","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir T","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 2019;94:1353\u20131363."},{"key":"B131","series-title":"Lancet Oncol","first-page":"1409","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O\u2019Brien S","year":"2016","unstructured":"O\u2019Brien S, Jones JA, Coutre SE, Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 2016;17:1409\u20131418."},{"key":"B132","series-title":"Blood","first-page":"Abstract 202","article-title":"Extended follow-up of ALPINE Randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R\/R CLL\/SLL)","volume":"142","author":"Brown JR","year":"2023","unstructured":"Brown JR, Eichhorst BF, Lamanna N, Extended follow-up of ALPINE Randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R\/R CLL\/SLL). Blood 2023;142(Suppl 1):Abstract 202."},{"key":"B133","series-title":"N Engl J Med","first-page":"33","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato AR","year":"2023","unstructured":"Mato AR, Woyach JA, Brown JR, Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med 2023;389:33\u201344."},{"key":"B134","series-title":"Blood","first-page":"Abstract 325","article-title":"Pirtobrutinib in post-cBTKi CLL\/SLL: \u223c30 months follow-up and subgroup analysis with\/without prior BCL2i from the phase 1\/2 BRUIN study","volume":"142","author":"Woyach JA","year":"2023","unstructured":"Woyach JA, Brown JR, Ghia P, Pirtobrutinib in post-cBTKi CLL\/SLL: \u223c30 months follow-up and subgroup analysis with\/without prior BCL2i from the phase 1\/2 BRUIN study. Blood 2023;142(Suppl 1): Abstract 325."},{"key":"B135","series-title":"N Engl J Med","first-page":"1107","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour JF","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018;378:1107\u20131120."},{"key":"B136","series-title":"J Clin Oncol","first-page":"1973","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial","volume":"36","author":"Stilgenbauer S","year":"2018","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol 2018;36:1973\u20131980."},{"key":"B137","series-title":"Lancet Oncol","first-page":"65","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones JA","year":"2018","unstructured":"Jones JA, Mato AR, Wierda WG, Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018;19:65\u201375."},{"key":"B138","series-title":"Blood","first-page":"1704","article-title":"Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy","volume":"131","author":"Coutre S","year":"2018","unstructured":"Coutre S, Choi M, Furman RR, Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood 2018;131:1704\u20131711."},{"key":"B139","series-title":"Br J Haematol","first-page":"656","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis","volume":"185","author":"Eyre TA","year":"2019","unstructured":"Eyre TA, Kirkwood AA, Gohill S, Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. Br J Haematol 2019;185:656\u2013669."},{"key":"B140","series-title":"Br J Haematol","first-page":"e8","article-title":"Venetoclax in CLL patients who progress after B-cell receptor inhibitor treatment: a retrospective multi-centre Italian experience","volume":"187","author":"Innocenti I","year":"2019","unstructured":"Innocenti I, Morelli F, Autore F, Venetoclax in CLL patients who progress after B-cell receptor inhibitor treatment: a retrospective multi-centre Italian experience. Br J Haematol 2019;187:e8\u201311."},{"key":"B141","series-title":"Blood","first-page":"111","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts AW","year":"2019","unstructured":"Roberts AW, Ma S, Kipps TJ, Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood 2019;134:111\u2013122."},{"key":"B142","series-title":"Ann Oncol","first-page":"1050","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","volume":"28","author":"Mato AR","year":"2017","unstructured":"Mato AR, Hill BT, Lamanna N, Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Ann Oncol 2017;28:1050\u20131056."},{"key":"B143","series-title":"Br J Haematol","first-page":"961","article-title":"Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor","volume":"185","author":"Wierda WG","year":"2019","unstructured":"Wierda WG, Byrd JC, Davids MS, Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. Br J Haematol 2019;185:961\u2013966."},{"key":"B144","series-title":"Blood Adv","first-page":"4553","article-title":"Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen","volume":"6","author":"Thompson MC","year":"2022","unstructured":"Thompson MC, Harrup RA, Coombs CC, Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Adv 2022;6:4553\u20134557."},{"key":"B145","series-title":"Leuk Lymphoma","article-title":"Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma","author":"Lei MM","year":"Published online January 31, 2024","unstructured":"Lei MM, Sorial MN, Lou U, Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Leuk Lymphoma Published online January 31, 2024. doi: 10.1080\/10428194.2024.2310144"},{"key":"B146","series-title":"Blood","first-page":"3390","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown JR","year":"2014","unstructured":"Brown JR, Byrd JC, Coutre SE, Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia. Blood 2014;123:3390\u20133397."},{"key":"B147","series-title":"J Clin Oncol","first-page":"1391","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman JP","year":"2019","unstructured":"Sharman JP, Coutre SE, Furman RR, Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol 2019;37:1391\u20131402."},{"key":"B148","series-title":"N Engl J Med","first-page":"1008","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal AK","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:1008\u20131018."},{"key":"B149","series-title":"Blood","first-page":"2446","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn IW","year":"2018","unstructured":"Flinn IW, Hillmen P, Montillo M, The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood 2018;132:2446\u20132455."},{"key":"B150","series-title":"J Clin Oncol","first-page":"912","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Flinn IW","year":"2019","unstructured":"Flinn IW, Miller CB, Ardeshna KM, DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol 2019;37:912\u2013922."},{"key":"B151","series-title":"Clin Cancer Res","first-page":"2096","article-title":"Efficacy and safety of duvelisib following disease progression on ofatumumab in patients with relapsed\/refractory CLL or SLL in the DUO Crossover Extension Study","volume":"26","author":"Davids MS","year":"2020","unstructured":"Davids MS, Kuss BJ, Hillmen P, Efficacy and safety of duvelisib following disease progression on ofatumumab in patients with relapsed\/refractory CLL or SLL in the DUO Crossover Extension Study. Clin Cancer Res 2020;26:2096\u20132103."},{"key":"B152","series-title":"J Clin Oncol","first-page":"1756","article-title":"Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia","volume":"28","author":"Robak T","year":"2010","unstructured":"Robak T, Dmoszynska A, Solal-C\u00e9ligny P, Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756\u20131765."},{"key":"B153","series-title":"Blood","first-page":"3016","article-title":"Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL","volume":"117","author":"Badoux XC","year":"2011","unstructured":"Badoux XC, Keating MJ, Wang X, Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011;117:3016\u20133024."},{"key":"B154","series-title":"J Clin Oncol","first-page":"3559","article-title":"Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"29","author":"Fischer K","year":"2011","unstructured":"Fischer K, Cramer P, Busch R, Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:3559\u20133566."},{"key":"B155","series-title":"Leukemia","first-page":"2048","article-title":"Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia","volume":"22","author":"Castro JE","year":"2008","unstructured":"Castro JE, Sandoval-Sus JD, Bole J, Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008;22:2048\u20132053."},{"key":"B156","series-title":"Haematologica","first-page":"475","article-title":"High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy","volume":"93","author":"Dungarwalla M","year":"2008","unstructured":"Dungarwalla M, Evans SO, Riley U, High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica 2008;93:475\u2013476."},{"key":"B157","series-title":"J Clin Oncol","first-page":"584","article-title":"Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia","volume":"31","author":"Badoux XC","year":"2013","unstructured":"Badoux XC, Keating MJ, Wen S, Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2013;31:584\u2013591."},{"key":"B158","series-title":"Blood Cancer J","first-page":"e404","article-title":"Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial","volume":"6","author":"B\u00fchler A","year":"2016","unstructured":"B\u00fchler A, Wendtner CM, Kipps TJ, Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J 2016;6:e404."},{"key":"B159","series-title":"Leuk Res","first-page":"78","article-title":"Results of a phase II study of lenalidomide and rituximab for refractory\/relapsed chronic lymphocytic leukemia","volume":"47","author":"Chavez JC","year":"2016","unstructured":"Chavez JC, Piris-Villaespesa M, Dalia S, Results of a phase II study of lenalidomide and rituximab for refractory\/relapsed chronic lymphocytic leukemia. Leuk Res 2016;47:78\u201383."},{"key":"B160","series-title":"Cancer","first-page":"2360","article-title":"Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence","volume":"116","author":"Faderl S","year":"2010","unstructured":"Faderl S, Ferrajoli A, Wierda W, Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer 2010;116:2360\u20132365."},{"key":"B161","series-title":"Blood","first-page":"3278","article-title":"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions","volume":"103","author":"Lozanski G","year":"2004","unstructured":"Lozanski G, Heerema NA, Flinn IW, Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278\u20133281."},{"key":"B162","series-title":"Ann Hematol","first-page":"267","article-title":"Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients","volume":"93","author":"Fiegl M","year":"2014","unstructured":"Fiegl M, Stauder R, Steurer M, Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Ann Hematol 2014;93:267\u2013277."},{"key":"B163","series-title":"Blood","first-page":"Abstract 504","article-title":"Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations","volume":"134","author":"Woyach J, Huang Y, Rogers K","year":"2019","unstructured":"Woyach J, Huang Y, Rogers K, Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations. Blood 2019;134(Suppl 1):Abstract 504."},{"key":"B164","series-title":"Blood","first-page":"1469","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn IE","year":"2017","unstructured":"Ahn IE, Underbayev C, Albitar A, Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 2017;129:1469\u20131479."},{"key":"B165","series-title":"Blood","first-page":"Abstract 326","article-title":"Genomic evolution and resistance during pirtobrutinib therapy in covalent BTK-inhibitor (cBTKi) pre-treated chronic lymphocytic leukemia patients: updated analysis from the BRUIN Study","volume":"142","author":"Brown JR","year":"2023","unstructured":"Brown JR, Desikan SP, Nguyen B, Genomic evolution and resistance during pirtobrutinib therapy in covalent BTK-inhibitor (cBTKi) pre-treated chronic lymphocytic leukemia patients: updated analysis from the BRUIN Study. Blood 2023;142(Suppl 1):Abstract 326."},{"key":"B166","series-title":"Cancer Discov","first-page":"342","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery P","year":"2019","unstructured":"Blombery P, Anderson MA, Gong JN, Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov 2019;9:342\u2013353."},{"key":"B167","series-title":"Haematologica","first-page":"e434","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch E","year":"2019","unstructured":"Tausch E, Close W, Dolnik A, Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica 2019;104:e434\u2013437."},{"key":"B168","series-title":"Blood","first-page":"Abstract 4320","article-title":"Outcomes of ibrutinib (Ibr) therapy in Ibr-na\u00efve patients (pts) with chronic lymphocytic leukemia (CLL) progressing after venetoclax (Ven)","volume":"134","author":"Brown JR","year":"2019","unstructured":"Brown JR, Davids MS, Chang JE, Outcomes of ibrutinib (Ibr) therapy in Ibr-na\u00efve patients (pts) with chronic lymphocytic leukemia (CLL) progressing after venetoclax (Ven). Blood 2019;134(Suppl 1):Abstract 4320."},{"key":"B169","series-title":"Blood","first-page":"2266","article-title":"BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax","volume":"135","author":"Lin VS","year":"2020","unstructured":"Lin VS, Lew TE, Handunnetti SM, BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood 2020;135:2266\u20132270."},{"key":"B170","series-title":"Clin Cancer Res","first-page":"3589","article-title":"Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy","volume":"26","author":"Mato AR","year":"2020","unstructured":"Mato AR, Roeker LE, Jacobs R, Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy. Clin Cancer Res 2020;26:3589\u20133596."},{"key":"B171","series-title":"Blood","first-page":"687","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour JF","year":"2023","unstructured":"Seymour JF, Byrd JC, Ghia P, Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood 2023;142:687\u2013699."},{"key":"B172","series-title":"Blood Adv","first-page":"1553","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan FT","year":"2019","unstructured":"Awan FT, Schuh A, Brown JR, Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv 2019;3:1553\u20131562."},{"key":"B173","series-title":"Haematologica","first-page":"2364","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers KA","year":"2021","unstructured":"Rogers KA, Thompson PA, Allan JN, Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia. Haematologica 2021;106:2364\u20132373."},{"key":"B174","series-title":"Cancer Med","first-page":"3390","article-title":"The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice","volume":"9","author":"Parikh SA","year":"2020","unstructured":"Parikh SA, Achenbach SJ, Call TG, The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Med 2020;9:3390\u20133399."},{"key":"B175","series-title":"J Clin Oncol","first-page":"Abstract 7537","article-title":"Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L)","volume":"41","author":"Rogers KA","year":"2023","unstructured":"Rogers KA, Lu X, Emond B, Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L). J Clin Oncol 2023;41(Suppl):Abstract 7537."},{"key":"B176","series-title":"HemaSphere","first-page":"e24922b0","article-title":"P621: real-world dosing patterns and time to next treatment of previously untreated patients with CLL\/SLL with or without ibrutinib dose reduction following an adverse event","volume":"7","author":"Shadman M","year":"2023","unstructured":"Shadman M, Srivastava B, Patel S, P621: real-world dosing patterns and time to next treatment of previously untreated patients with CLL\/SLL with or without ibrutinib dose reduction following an adverse event. HemaSphere 2023;7(Suppl):e24922b0."},{"key":"B177","series-title":"J Clin Oncol","first-page":"Abstract 7538","article-title":"Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: pooled analysis of 10 clinical trials","volume":"41","author":"Stephens DM","year":"2023","unstructured":"Stephens DM, Brown JR, Ma S, Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: pooled analysis of 10 clinical trials. J Clin Oncol 2023; 41(Suppl):Abstract 7538."},{"key":"B178","series-title":"N Engl J Med","first-page":"311","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts AW","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 2016;374:311\u2013322."},{"key":"B179","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"S302","article-title":"Modified venetoclax dose ramp-up in select high-risk patients with chronic lymphocytic leukemia (CLL) with progression after B-cell receptor pathway inhibitors (BCRi)","volume":"17","author":"Davids M","year":"2017","unstructured":"Davids M, Jones J, Eradat H, Modified venetoclax dose ramp-up in select high-risk patients with chronic lymphocytic leukemia (CLL) with progression after B-cell receptor pathway inhibitors (BCRi). Clin Lymphoma Myeloma Leuk 2017;17(Suppl 2):S302."},{"key":"B180","series-title":"Blood Adv","first-page":"4860","article-title":"Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists","volume":"4","author":"Koenig KL","year":"2020","unstructured":"Koenig KL, Huang Y, Dotson EK, Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists. Blood Adv 2020;4:4860\u20134863."},{"key":"B181","series-title":"Blood","first-page":"195","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune- mediated hepatotoxicity","volume":"128","author":"Lampson BL","year":"2016","unstructured":"Lampson BL, Kasar SN, Matos TR, Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune- mediated hepatotoxicity. Blood 2016;128:195\u2013203."},{"key":"B182","series-title":"Lancet Oncol","first-page":"297","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz AD","year":"2017","unstructured":"Zelenetz AD, Barrientos JC, Brown JR, Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2017;18:297\u2013311."},{"key":"B183","series-title":"J Clin Oncol","first-page":"3433","article-title":"Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia","volume":"23","author":"Moreno C","year":"2005","unstructured":"Moreno C, Villamor N, Colomer D, Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005;23:3433\u20133438."},{"key":"B184","series-title":"J Clin Oncol","first-page":"5094","article-title":"Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis","volume":"26","author":"Schetelig J","year":"2008","unstructured":"Schetelig J, van Biezen A, Brand R, Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 2008;26:5094\u20135100."},{"key":"B185","series-title":"J Clin Oncol","first-page":"4912","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror ML","year":"2008","unstructured":"Sorror ML, Storer BE, Sandmaier BM, Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008;26:4912\u20134920."},{"key":"B186","series-title":"Cancer","first-page":"4679","article-title":"Nonmyeloablative allogeneic stem cell transplantation in relapsed\/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome","volume":"117","author":"Khouri IF","year":"2011","unstructured":"Khouri IF, Bassett R, Poindexter N, Nonmyeloablative allogeneic stem cell transplantation in relapsed\/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer 2011;117:4679\u20134688."},{"key":"B187","series-title":"Leukemia","first-page":"362","article-title":"Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome","volume":"27","author":"Brown JR","year":"2013","unstructured":"Brown JR, Kim HT, Armand P, Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia 2013;27:362\u2013369."},{"key":"B188","series-title":"Ann Oncol","first-page":"200","article-title":"The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison","volume":"25","author":"Herth I","year":"2014","unstructured":"Herth I, Dietrich S, Benner A, The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. Ann Oncol 2014;25:200\u2013206."},{"key":"B189","series-title":"Leuk Lymphoma","first-page":"711","article-title":"Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis","volume":"56","author":"Poon ML","year":"2015","unstructured":"Poon ML, Fox PS, Samuels BI, Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis. Leuk Lymphoma 2015;56:711\u2013715."},{"key":"B190","series-title":"Br J Haematol","first-page":"82","article-title":"Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia","volume":"159","author":"Jaglowski SM","year":"2012","unstructured":"Jaglowski SM, Ruppert AS, Heerema NA, Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia. Br J Haematol 2012;159:82\u201387."},{"key":"B191","series-title":"Clin Cancer Res","first-page":"5143","article-title":"Prognostic score and cytogenetic risk classification for chronic lymphocytic leukemia patients: Center for International Blood and Marrow Transplant Research Report","volume":"25","author":"Kim HT","year":"2019","unstructured":"Kim HT, Ahn KW, Hu ZH, Prognostic score and cytogenetic risk classification for chronic lymphocytic leukemia patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res 2019;25:5143\u20135155."},{"key":"B192","series-title":"Biol Blood Marrow Transplant","first-page":"2117","article-title":"Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation","volume":"22","author":"Kharfan-Dabaja MA","year":"2016","unstructured":"Kharfan-Dabaja MA, Kumar A, Hamadani M, Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2016;22:2117\u20132125."},{"key":"B193","series-title":"Blood","first-page":"2912","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror ML","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912\u20132919."},{"key":"B194","series-title":"Br J Haematol","first-page":"574","article-title":"Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation","volume":"170","author":"ElSawy M","year":"2015","unstructured":"ElSawy M, Storer BE, Pulsipher MA, Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. Br J Haematol 2015;170:574\u2013583."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/3\/article-p175.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/3\/article-p175.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/3\/article-p175.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T16:12:24Z","timestamp":1713283944000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/3\/article-p175.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":194,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.0018","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}